Index RUT
P/E -
EPS (ttm) -3.97
Insider Own 37.13%
Shs Outstand 61.47M
Perf Week 3.58%
Market Cap 2.14B
Forward P/E -
EPS next Y -3.32
Insider Trans -9.90%
Shs Float 50.99M
Perf Month -0.26%
Income -257.40M
PEG -
EPS next Q -0.75
Inst Own 58.91%
Short Float 17.70%
Perf Quarter 20.52%
Sales 0.00M
P/S -
EPS this Y 21.43%
Inst Trans -3.15%
Short Ratio 7.19
Perf Half Y 268.82%
Book/sh 5.49
P/B 4.80
EPS next Y -7.10%
ROA -63.48%
Short Interest 9.02M
Perf Year 117.94%
Cash/sh 5.59
P/C 4.72
EPS next 5Y -
ROE -71.50%
52W Range 6.40 - 30.27
Perf YTD 98.27%
Dividend Est. -
P/FCF -
EPS past 5Y -106.26%
ROI -51.49%
52W High -12.88%
Beta 1.00
Dividend TTM -
Quick Ratio 21.83
Sales past 5Y 0.00%
Gross Margin -
52W Low 312.04%
ATR (14) 1.58
Dividend Ex-Date -
Current Ratio 21.83
EPS Y/Y TTM -18.88%
Oper. Margin 0.00%
RSI (14) 54.19
Volatility 6.59% 5.76%
Employees 141
Debt/Eq 0.06
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 39.22
Option/Short Yes / Yes
LT Debt/Eq 0.05
EPS Q/Q -3.25%
Payout -
Rel Volume 0.47
Prev Close 26.08
Sales Surprise -100.00%
EPS Surprise -1.25%
Sales Q/Q -
Earnings May 02 AMC
Avg Volume 1.25M
Price 26.37
SMA20 3.62%
SMA50 0.28%
SMA200 65.61%
Trades
Volume 220,493
Change 1.11%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-30-24 Initiated
Morgan Stanley
Overweight
$40
Feb-20-24 Initiated
H.C. Wainwright
Buy
$36
Feb-27-23 Upgrade
Raymond James
Outperform → Strong Buy
$16 → $27
Feb-15-23 Initiated
Oppenheimer
Outperform
$34
Jan-26-23 Initiated
Guggenheim
Buy
$33
Jul-20-22 Initiated
Chardan Capital Markets
Buy
$17
Jul-12-22 Initiated
Raymond James
Outperform
$15
Oct-12-20 Initiated
Stifel
Buy
$29
Oct-12-20 Initiated
Piper Sandler
Overweight
$34
Oct-12-20 Initiated
JP Morgan
Overweight
$27
Oct-12-20 Initiated
Jefferies
Buy
$47
Show Previous Ratings
May-04-24 05:31AM
May-02-24 11:52PM
04:10PM
Apr-30-24 07:32AM
Mar-27-24 04:05PM
08:30AM
Loading…
08:30AM
Mar-25-24 12:28PM
(Associated Press Finance) -7.72%
07:30AM
Mar-13-24 07:30AM
Mar-07-24 01:19PM
Mar-05-24 10:53AM
07:30AM
Mar-02-24 12:00AM
Feb-29-24 03:02AM
Feb-14-24 04:15PM
07:30AM
Loading…
Feb-01-24 07:30AM
Jan-26-24 11:01PM
Jan-22-24 10:14PM
Jan-12-24 01:12PM
Jan-11-24 04:05PM
Jan-05-24 09:02AM
07:30AM
Jan-04-24 10:46PM
04:37PM
12:39PM
Jan-03-24 04:25PM
02:46PM
(The Wall Street Journal)
02:01PM
(The Wall Street Journal)
08:19AM
06:30AM
04:05PM
Loading…
Jan-02-24 04:05PM
Nov-13-23 06:59PM
Nov-07-23 07:30AM
Oct-31-23 05:36AM
01:11AM
Oct-30-23 07:30AM
Sep-28-23 07:30AM
Sep-20-23 04:05PM
Sep-15-23 01:52PM
Sep-14-23 01:22PM
Sep-05-23 07:30AM
Aug-28-23 10:22AM
Aug-03-23 07:30AM
Jun-16-23 08:46AM
Jun-01-23 07:30AM
May-25-23 07:30AM
May-17-23 11:25AM
07:30AM
May-11-23 07:30AM
May-03-23 07:35AM
May-02-23 04:46PM
Mar-23-23 07:30AM
Mar-20-23 07:30AM
Mar-07-23 07:30AM
Mar-02-23 07:30AM
Mar-01-23 09:00AM
(Yahoo Finance Video) +5.82%
Feb-27-23 04:40PM
Feb-05-23 05:03AM
Jan-19-23 08:23AM
Jan-18-23 08:49AM
Jan-10-23 12:00PM
Jan-03-23 07:30AM
Dec-16-22 09:55AM
Dec-09-22 09:55AM
Dec-08-22 08:10AM
Nov-30-22 09:55AM
Nov-03-22 07:30AM
Nov-02-22 07:30AM
Oct-31-22 07:30AM
Oct-12-22 06:45AM
(American City Business Journals)
Oct-11-22 04:10PM
Sep-27-22 07:30AM
Sep-12-22 07:00AM
Sep-06-22 04:30PM
07:01AM
07:00AM
Aug-29-22 07:30AM
Aug-10-22 07:30AM
Aug-04-22 07:30AM
Jul-18-22 10:00AM
Jul-12-22 02:54PM
07:30AM
Jul-05-22 07:30AM
Jul-01-22 06:58AM
Jun-03-22 07:30AM
May-16-22 07:30AM
May-02-22 04:05PM
Mar-17-22 08:45AM
Mar-10-22 07:30AM
Mar-03-22 07:30AM
Feb-02-22 01:38PM
Jan-22-22 08:06AM
Jan-18-22 04:18PM
08:00AM
Jan-05-22 07:30AM
Dec-03-21 03:30PM
Dec-02-21 08:30AM
Nov-04-21 07:30AM
Oct-26-21 10:41AM
Oct-13-21 07:45AM
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Farwell Wildon Chief Medical Officer Mar 12 '24 Sale 25.58 1,030 26,347 150,560 Mar 12 09:58 PM Brumm Joshua T CEO & President Mar 11 '24 Option Exercise 5.54 50,000 277,000 604,385 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 11 '24 Option Exercise 5.54 17,825 98,750 159,009 Mar 13 06:04 AM Brumm Joshua T CEO & President Mar 11 '24 Sale 25.67 66,387 1,704,142 537,998 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 11 '24 Sale 25.50 19,601 499,842 139,408 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 11 '24 Sale 25.28 2,672 67,542 119,283 Mar 12 09:57 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 11 '24 Sale 25.70 2,292 58,904 156,800 Mar 13 06:04 AM Beskrovnaya Oxana Chief Scientific Officer Mar 11 '24 Sale 25.70 2,081 53,482 152,352 Mar 12 09:42 PM Farwell Wildon Chief Medical Officer Mar 11 '24 Sale 25.70 1,585 40,734 151,590 Mar 12 09:58 PM Brumm Joshua T CEO & President Mar 08 '24 Option Exercise 5.54 363,343 2,012,920 917,728 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 08 '24 Option Exercise 5.54 90,000 498,600 231,184 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 08 '24 Option Exercise 5.54 86,252 477,836 208,207 Mar 12 09:57 PM Brumm Joshua T CEO & President Mar 08 '24 Sale 25.93 363,343 9,421,634 554,385 Mar 12 09:56 PM McNeill Jonathan Chief Business Officer Mar 08 '24 Sale 26.24 90,000 2,361,531 141,184 Mar 13 06:04 AM Scalzo Richard William SVP, Head of Finance & Admin. Mar 08 '24 Sale 26.22 86,252 2,261,465 121,955 Mar 12 09:57 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 08 '24 Sale 26.67 27,199 725,344 159,092 Mar 13 06:04 AM Farwell Wildon Chief Medical Officer Mar 07 '24 Sale 25.86 9,921 256,585 153,175 Mar 11 09:52 PM Brumm Joshua T CEO & President Mar 07 '24 Sale 25.85 9,086 234,873 554,385 Mar 11 09:57 PM McNeill Jonathan Chief Business Officer Mar 07 '24 Sale 25.85 2,434 62,919 141,184 Mar 11 09:50 PM Beskrovnaya Oxana Chief Scientific Officer Mar 07 '24 Sale 25.85 2,373 61,342 154,433 Mar 11 09:56 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 07 '24 Sale 25.85 2,273 58,757 121,955 Mar 11 09:45 PM HIGH SUSANNA GATTI Chief Operating Officer Mar 07 '24 Sale 25.85 1,591 41,127 186,291 Mar 11 09:56 PM Brumm Joshua T CEO & President Mar 01 '24 Option Exercise 5.54 94,480 523,419 657,951 Mar 01 09:38 PM McNeill Jonathan Chief Business Officer Mar 01 '24 Option Exercise 0.73 24,260 17,710 167,878 Mar 01 09:37 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 01 '24 Option Exercise 1.03 9,311 9,590 133,539 Mar 01 09:37 PM Brumm Joshua T CEO & President Mar 01 '24 Sale 29.04 94,480 2,743,718 563,471 Mar 01 09:38 PM Rhodes Jason P Director Mar 01 '24 Sale 30.05 46,534 1,398,347 847,388 Mar 05 05:08 PM Atlas Venture Opportunity Fund 10% Owner Mar 01 '24 Sale 30.05 29,435 884,522 1,458,691 Mar 05 05:07 PM McNeill Jonathan Chief Business Officer Mar 01 '24 Sale 28.63 24,260 694,495 143,618 Mar 01 09:37 PM Atlas Venture Opportunity Fund 10% Owner Mar 01 '24 Sale 30.05 17,099 513,825 847,388 Mar 05 05:07 PM Scalzo Richard William SVP, Head of Finance & Admin. Mar 01 '24 Sale 28.25 9,311 262,999 124,228 Mar 01 09:37 PM Brumm Joshua T CEO & President Feb 29 '24 Option Exercise 5.54 5,520 30,581 568,991 Mar 01 09:38 PM Scalzo Richard William SVP, Head of Finance & Admin. Feb 29 '24 Option Exercise 1.03 3,429 3,532 127,657 Mar 01 09:37 PM McNeill Jonathan Chief Business Officer Feb 29 '24 Option Exercise 0.73 4,268 3,116 147,886 Mar 01 09:37 PM Brumm Joshua T CEO & President Feb 29 '24 Sale 27.50 5,520 151,800 563,471 Mar 01 09:38 PM McNeill Jonathan Chief Business Officer Feb 29 '24 Sale 27.50 4,268 117,370 143,618 Mar 01 09:37 PM Scalzo Richard William SVP, Head of Finance & Admin. Feb 29 '24 Sale 27.50 3,429 94,298 124,228 Mar 01 09:37 PM Rhodes Jason P Director Feb 28 '24 Sale 24.84 190,920 4,741,804 864,487 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 28 '24 Sale 24.84 154,674 3,841,576 5,698,091 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 28 '24 Sale 24.84 36,246 900,228 864,487 Feb 28 07:13 PM Rhodes Jason P Director Feb 27 '24 Sale 24.41 368,699 8,998,426 877,806 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 27 '24 Sale 24.41 298,702 7,290,088 5,852,765 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 27 '24 Sale 24.41 69,997 1,708,338 877,806 Feb 28 07:13 PM Rhodes Jason P Director Feb 26 '24 Sale 23.72 248,219 5,886,673 903,527 Feb 28 07:15 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 26 '24 Sale 23.72 201,095 4,769,096 6,151,467 Feb 28 07:13 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 26 '24 Sale 23.72 47,124 1,117,577 903,527 Feb 28 07:13 PM Rhodes Jason P Director Feb 23 '24 Sale 22.70 196,928 4,470,266 920,843 Feb 23 06:59 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 23 '24 Sale 22.70 159,542 3,621,603 6,352,562 Feb 23 06:58 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 23 '24 Sale 22.70 37,386 848,662 920,843 Feb 23 06:58 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 22 '24 Sale 22.66 119,360 2,704,698 6,512,104 Feb 23 06:58 PM Rhodes Jason P Director Feb 22 '24 Sale 22.66 119,360 2,704,698 6,512,104 Feb 23 06:59 PM Rhodes Jason P Director Feb 21 '24 Sale 22.57 184,501 4,164,817 6,631,464 Feb 23 06:59 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 21 '24 Sale 22.57 184,501 4,164,817 6,631,464 Feb 23 06:58 PM Rhodes Jason P Director Feb 20 '24 Sale 22.72 169,539 3,852,653 6,815,965 Feb 20 06:36 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 20 '24 Sale 22.72 169,539 3,852,653 6,815,965 Feb 20 06:35 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 16 '24 Sale 23.14 162,707 3,765,040 6,985,504 Feb 20 06:35 PM Rhodes Jason P Director Feb 16 '24 Sale 23.14 162,707 3,765,040 6,985,504 Feb 20 06:36 PM Rhodes Jason P Director Feb 15 '24 Sale 23.89 177,906 4,249,600 7,148,211 Feb 20 06:36 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 15 '24 Sale 23.89 177,906 4,249,600 7,148,211 Feb 20 06:35 PM Farwell Wildon Chief Medical Officer Feb 12 '24 Sale 25.07 5,493 137,710 163,503 Feb 14 04:27 PM McNeill Jonathan Chief Business Officer Jan 26 '24 Option Exercise 0.73 20,000 14,600 163,618 Jan 26 07:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 26 '24 Option Exercise 1.03 13,000 13,390 137,228 Jan 26 07:47 PM McNeill Jonathan Chief Business Officer Jan 26 '24 Sale 24.53 20,000 490,510 143,618 Jan 26 07:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 26 '24 Sale 24.34 13,000 316,420 124,228 Jan 26 07:47 PM Farwell Wildon Chief Medical Officer Jan 26 '24 Sale 25.00 100 2,500 168,996 Jan 26 07:49 PM Kersten Dirk Director Jan 09 '24 Buy 17.50 1,714,285 29,999,988 6,416,793 Jan 11 04:31 PM Brumm Joshua T CEO & President Jan 04 '24 Option Exercise 5.16 218,536 1,127,092 803,507 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 04 '24 Option Exercise 1.03 22,674 23,354 199,259 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 04 '24 Option Exercise 0.73 2,009 1,467 145,627 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 04 '24 Sale 18.51 218,536 4,045,958 584,971 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 04 '24 Sale 18.13 42,453 769,673 156,806 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 04 '24 Sale 18.04 2,009 36,242 143,618 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 03 '24 Option Exercise 1.03 51,183 52,718 636,154 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 03 '24 Option Exercise 1.03 45,326 46,686 221,911 Jan 04 09:48 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 03 '24 Option Exercise 1.03 13,000 13,390 137,228 Jan 04 09:46 PM McNeill Jonathan Chief Business Officer Jan 03 '24 Option Exercise 0.73 17,991 13,133 161,609 Jan 04 09:47 PM Brumm Joshua T CEO & President Jan 03 '24 Sale 19.28 51,183 986,957 584,971 Jan 04 09:49 PM Beskrovnaya Oxana Chief Scientific Officer Jan 03 '24 Sale 18.98 45,326 860,313 176,585 Jan 04 09:48 PM McNeill Jonathan Chief Business Officer Jan 03 '24 Sale 18.74 17,991 337,062 143,618 Jan 04 09:47 PM Scalzo Richard William SVP, Head of Finance & Admin. Jan 03 '24 Sale 18.81 13,000 244,530 124,228 Jan 04 09:46 PM McNeill Jonathan Chief Business Officer Jan 02 '24 Sale 13.10 11,900 155,890 143,618 Jan 04 09:47 PM Scalzo Richard William See Remarks Dec 14 '23 Sale 12.02 2,376 28,560 124,228 Dec 14 04:59 PM Farwell Wildon Chief Medical Officer Dec 12 '23 Sale 10.55 978 10,318 169,096 Dec 12 05:33 PM Brumm Joshua T See Remarks Dec 11 '23 Sale 10.72 7,585 81,311 584,971 Dec 12 05:33 PM Farwell Wildon Chief Medical Officer Dec 11 '23 Sale 10.72 1,688 18,095 170,074 Dec 12 05:33 PM HIGH SUSANNA GATTI Chief Operating Officer Dec 11 '23 Sale 10.72 1,616 17,324 187,882 Dec 12 05:34 PM Beskrovnaya Oxana Chief Scientific Officer Dec 11 '23 Sale 10.72 1,467 15,726 176,585 Dec 12 05:32 PM Scalzo Richard William See Remarks Dec 11 '23 Sale 10.72 1,380 14,794 126,604 Dec 12 05:35 PM McNeill Jonathan Chief Business Officer Dec 11 '23 Sale 10.72 1,245 13,346 155,518 Dec 12 05:34 PM Scalzo Richard William See Remarks Dec 06 '23 Sale 12.01 1,872 22,483 127,984 Dec 06 06:13 PM Scalzo Richard William See Remarks Dec 04 '23 Sale 12.01 681 8,179 129,856 Dec 06 06:13 PM HIGH SUSANNA GATTI Chief Operating Officer Nov 02 '23 Sale 7.40 9,939 73,549 94,605 Nov 02 05:16 PM Brumm Joshua T See Remarks Sep 18 '23 Sale 9.41 12,032 113,221 233,679 Sep 20 04:47 PM HIGH SUSANNA GATTI Chief Operating Officer Sep 18 '23 Sale 9.41 2,672 25,144 104,544 Sep 20 04:48 PM Beskrovnaya Oxana Chief Scientific Officer Sep 18 '23 Sale 9.41 1,436 13,513 84,334 Sep 20 04:47 PM Scalzo Richard William See Remarks Sep 18 '23 Sale 9.41 1,290 12,139 40,795 Sep 20 04:49 PM McNeill Jonathan Chief Business Officer Sep 18 '23 Sale 9.41 1,261 11,866 60,605 Sep 20 04:49 PM Brumm Joshua T See Remarks Sep 12 '23 Sale 10.41 7,672 79,866 245,711 Sep 13 07:50 PM Farwell Wildon Chief Medical Officer Sep 12 '23 Sale 10.41 1,707 17,770 89,250 Sep 13 07:56 PM HIGH SUSANNA GATTI Chief Operating Officer Sep 12 '23 Sale 10.41 1,635 17,020 107,216 Sep 13 07:51 PM
Index -
P/E -
EPS (ttm) -2.78
Insider Own 76.37%
Shs Outstand 27.61M
Perf Week 19.23%
Market Cap 45.77M
Forward P/E -
EPS next Y -0.96
Insider Trans 1.73%
Shs Float 8.72M
Perf Month 3.33%
Income -76.40M
PEG -
EPS next Q -0.11
Inst Own 15.95%
Short Float 4.35%
Perf Quarter 85.07%
Sales 0.00M
P/S -
EPS this Y 46.94%
Inst Trans -4.43%
Short Ratio 0.31
Perf Half Y -50.40%
Book/sh 1.33
P/B 0.93
EPS next Y 34.58%
ROA -76.37%
Short Interest 0.38M
Perf Year -57.68%
Cash/sh 1.21
P/C 1.02
EPS next 5Y -
ROE -107.25%
52W Range 0.49 - 3.25
Perf YTD 125.45%
Dividend Est. -
P/FCF -
EPS past 5Y -44.91%
ROI -169.90%
52W High -61.85%
Beta -0.05
Dividend TTM -
Quick Ratio 3.02
Sales past 5Y 0.00%
Gross Margin -
52W Low 153.06%
ATR (14) 0.14
Dividend Ex-Date -
Current Ratio 3.02
EPS Y/Y TTM 13.71%
Oper. Margin 0.00%
RSI (14) 57.88
Volatility 11.53% 12.46%
Employees 73
Debt/Eq 0.34
Sales Y/Y TTM -
Profit Margin -
Recom 1.50
Target Price 5.50
Option/Short No / Yes
LT Debt/Eq 0.22
EPS Q/Q 21.81%
Payout -
Rel Volume 0.27
Prev Close 1.18
Sales Surprise -
EPS Surprise -2.81%
Sales Q/Q -
Earnings Apr 01 AMC
Avg Volume 1.22M
Price 1.24
SMA20 5.44%
SMA50 28.87%
SMA200 -16.51%
Trades
Volume 118,646
Change 5.08%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated
Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated
H.C. Wainwright
Buy
$36
Nov-16-21 Initiated
Raymond James
Outperform
$31
Nov-16-21 Initiated
Morgan Stanley
Overweight
$32
Nov-16-21 Initiated
Guggenheim
Buy
$40
Nov-16-21 Initiated
Cowen
Outperform
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
Loading…
07:00AM
06:45AM
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
08:30AM
Loading…
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
07:30AM
Loading…
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 733 469 2,019,563 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 267 171 734,546 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 1,540 1,278 2,020,296 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 560 465 734,813 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 1,566 1,362 2,021,836 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 569 495 735,373 Jan 16 06:16 PM
Index RUT
P/E -
EPS (ttm) -0.95
Insider Own 60.11%
Shs Outstand 40.10M
Perf Week 6.82%
Market Cap 485.45M
Forward P/E -
EPS next Y -1.69
Insider Trans -0.13%
Shs Float 16.26M
Perf Month 11.31%
Income -30.82M
PEG -
EPS next Q -0.31
Inst Own 43.16%
Short Float 4.96%
Perf Quarter 35.03%
Sales 0.00M
P/S -
EPS this Y -68.92%
Inst Trans -
Short Ratio 5.36
Perf Half Y 81.28%
Book/sh 6.71
P/B 1.78
EPS next Y -28.37%
ROA -10.70%
Short Interest 0.81M
Perf Year 150.21%
Cash/sh 6.60
P/C 1.80
EPS next 5Y -
ROE -11.05%
52W Range 4.31 - 12.42
Perf YTD 8.57%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -11.32%
52W High -4.11%
Beta 2.88
Dividend TTM -
Quick Ratio 50.29
Sales past 5Y 0.00%
Gross Margin -
52W Low 176.33%
ATR (14) 0.67
Dividend Ex-Date -
Current Ratio 50.29
EPS Y/Y TTM -5.40%
Oper. Margin 0.00%
RSI (14) 62.21
Volatility 4.17% 7.52%
Employees 30
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom 2.00
Target Price 9.55
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 41.33%
Payout -
Rel Volume 0.21
Prev Close 11.70
Sales Surprise -
EPS Surprise 44.90%
Sales Q/Q -
Earnings Mar 26 BMO
Avg Volume 150.39K
Price 11.91
SMA20 4.72%
SMA50 15.54%
SMA200 41.10%
Trades
Volume 11,856
Change 1.79%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-16-22 Downgrade
Jefferies
Buy → Hold
$30 → $3.60
Dec-15-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$5
Oct-10-22 Initiated
Morgan Stanley
Overweight
$34
Oct-10-22 Initiated
Jefferies
Buy
$30
Oct-10-22 Initiated
Cowen
Outperform
Apr-15-24 07:00PM
Mar-28-24 08:30AM
Mar-26-24 09:02PM
01:53PM
08:05AM
04:00PM
Loading…
Feb-26-24 04:00PM
Jan-04-24 08:00AM
Dec-29-23 12:00PM
Dec-08-23 01:05PM
Nov-09-23 09:30AM
08:30AM
Oct-31-23 08:30AM
Aug-31-23 08:30AM
Aug-10-23 08:10AM
Jul-26-23 09:40AM
08:30AM
Loading…
Jul-25-23 08:30AM
Jun-09-23 08:04AM
May-24-23 11:02AM
May-11-23 05:00PM
Mar-29-23 08:05AM
Dec-23-22 06:32AM
Dec-22-22 05:41AM
(American City Business Journals)
Dec-15-22 10:10AM
09:53AM
08:49AM
08:22AM
07:00AM
Nov-21-22 04:05PM
Nov-09-22 04:15PM
Nov-02-22 08:01AM
(Investor's Business Daily) -6.14%
04:10PM
Loading…
Sep-19-22 04:10PM
Sep-15-22 11:41AM
07:58AM
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. It focuses on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases. The company was founded on April 25, 2019 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Holles Natalie C. CEO Apr 11 '24 Option Exercise 4.20 13,558 56,944 1,232,394 Apr 15 04:14 PM Holles Natalie C. CEO Apr 11 '24 Sale 12.19 13,558 165,214 1,218,836 Apr 15 04:14 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Apr 04 '24 Option Exercise 4.20 1,107 4,649 1,107 Apr 08 05:21 PM Person Julie CHIEF ADMINISTRATIVE OFFICER Apr 04 '24 Sale 10.00 1,107 11,070 0 Apr 08 05:21 PM Person Julie Chief Administrative Officer Dec 05 '23 Option Exercise 4.20 12,863 54,025 12,863 Dec 07 04:04 PM Conner Edward R. Chief Medical Officer Dec 05 '23 Option Exercise 4.20 4,790 20,118 4,790 Dec 07 04:03 PM Person Julie Chief Administrative Officer Dec 05 '23 Sale 10.30 12,863 132,484 0 Dec 07 04:04 PM Conner Edward R. Chief Medical Officer Dec 05 '23 Sale 10.03 4,790 48,062 0 Dec 07 04:03 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite